{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:02:28Z","timestamp":1779123748686,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nowadays, various simulation approaches for evaluation and decision making in cancer screening can be found in the literature. This paper presents an overview of approaches used to assess screening programs for breast, lung, colorectal, prostate, and cervical cancers. Our main objectives are to describe methodological approaches and trends for different cancer sites and study populations, and to evaluate quality of cancer screening simulation studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature search was performed in Medline, Web of Science, and Scopus databases. The search time frame was limited to 1999\u20132018 and 7101 studies were found. Of them, 621 studies met inclusion criteria, and 587 full-texts were retrieved, with 300 of the studies chosen for analysis. Finally, 263 full texts were used in the analysis (37 were excluded during the analysis). A descriptive and trend analysis of models was performed using a checklist created for the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Currently, the most common methodological approaches in modeling cancer screening were individual-level Markov models (34% of the publications) and cohort-level Markov models (41%). The most commonly evaluated cancer types were breast (25%) and colorectal (24%) cancer. Studies on cervical cancer evaluated screening and vaccination (18%) or screening only (13%). Most studies have been conducted for North American (42%) and European (39%) populations. The number of studies with high quality scores increased over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that future directions for cancer screening modelling include individual-level Markov models complemented by screening trial data, and further effort in model validation and data openness.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-021-01713-5","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T13:10:52Z","timestamp":1640005852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cancer screening simulation models: a state of the art review"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0926-8439","authenticated-orcid":false,"given":"Aleksandr","family":"Bespalov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-3326","authenticated-orcid":false,"given":"Anton","family":"Barchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-4818","authenticated-orcid":false,"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-0245","authenticated-orcid":false,"given":"Jaakko","family":"Nevalainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"6","key":"1713_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1713_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. JAMA Oncol. 2019;5(12):1749.","journal-title":"JAMA Oncol"},{"issue":"19","key":"1713_CR3","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/cncr.28771","volume":"120","author":"T Onega","year":"2014","unstructured":"Onega T, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer. 2014;120(19):2955\u201364.","journal-title":"Cancer"},{"issue":"9","key":"1713_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrclinonc.2016.50","volume":"13","author":"Y Shieh","year":"2016","unstructured":"Shieh Y, et al. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016;13(9):550\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"1713_CR5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/(SICI)1097-0258(19981115)17:21<2509::AID-SIM949>3.0.CO;2-V","volume":"17","author":"KA Cronin","year":"1998","unstructured":"Cronin KA, et al. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. Stat Med. 1998;17(21):2509\u201323.","journal-title":"Stat Med"},{"issue":"7","key":"1713_CR6","doi-asserted-by":"publisher","first-page":"A465","DOI":"10.1016\/j.jval.2015.09.1217","volume":"18","author":"M Comas","year":"2015","unstructured":"Comas M, et al. Predicting future need of resources for adenoma surveillance from a population-based colorectal cancer screening program through discrete event simulation. Value Health. 2015;18(7):A465.","journal-title":"Value Health"},{"issue":"8","key":"1713_CR7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/cam4.1123","volume":"6","author":"NG Campos","year":"2017","unstructured":"Campos NG, et al. Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. Cancer Med. 2017;6(8):2008\u201314.","journal-title":"Cancer Med"},{"issue":"1","key":"1713_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1006\/cbmr.1998.1498","volume":"32","author":"F Loeve","year":"1999","unstructured":"Loeve F, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32(1):13\u201333.","journal-title":"Comput Biomed Res"},{"issue":"36","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jncimonographs\/lgj008","volume":"2","author":"J Mandelblatt","year":"2006","unstructured":"Mandelblatt J, et al. Chapter 8: The SPECTRUM Population Model of the impact of screening and treatment on US breast cancer trends from 1975 to 2000: principles and practice of the model methods. JNCI Monogr. 2006;2(36):47\u201355.","journal-title":"JNCI Monogr"},{"issue":"1","key":"1713_CR10","doi-asserted-by":"publisher","first-page":"44S","DOI":"10.1177\/0272989X17741634","volume":"38","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, et al. The Dana-Farber CISNET model for breast cancer screening strategies: an update. Med Decis Mak. 2018;38(1):44S-53S.","journal-title":"Med Decis Mak"},{"issue":"18","key":"1713_CR11","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1001\/jama.287.18.2372","volume":"287","author":"JS Mandelblatt","year":"2002","unstructured":"Mandelblatt JS. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287(18):2372.","journal-title":"JAMA"},{"issue":"8","key":"1713_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/annonc\/mdg323","volume":"14","author":"SJ Lee","year":"2003","unstructured":"Lee SJ. Modelling the early detection of breast cancer. Ann Oncol. 2003;14(8):1199\u2013202.","journal-title":"Ann Oncol"},{"issue":"16","key":"1713_CR13","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1002\/cncr.30070","volume":"122","author":"DA Joseph","year":"2016","unstructured":"Joseph DA, et al. Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity. Cancer. 2016;122(16):2479\u201386.","journal-title":"Cancer"},{"issue":"3","key":"1713_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/00005392-199909010-00032","volume":"162","author":"R Etzioni","year":"1999","unstructured":"Etzioni R, et al. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol. 1999;162(3):741\u20138.","journal-title":"J Urol"},{"issue":"18","key":"1713_CR15","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(18):1914\u201331. https:\/\/doi.org\/10.1001\/jama.2018.3712.","journal-title":"JAMA"},{"key":"1713_CR16","doi-asserted-by":"publisher","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020; 382(6):503\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa1911793.","DOI":"10.1056\/NEJMoa1911793."},{"issue":"5","key":"1713_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3747\/co.22.2889","volume":"22","author":"RG Koleva-Kolarova","year":"2015","unstructured":"Koleva-Kolarova RG, et al. To screen or not to screen for breast cancer? How do modelling studies answer the question? Curr Oncol. 2015;22(5):380.","journal-title":"Curr Oncol"},{"issue":"7","key":"1713_CR18","doi-asserted-by":"publisher","first-page":"A372","DOI":"10.1016\/j.jval.2016.09.150","volume":"19","author":"NS Silva","year":"2016","unstructured":"Silva NS. Comparison of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review. Value Health. 2016;19(7):A372.","journal-title":"Value Health"},{"key":"1713_CR19","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e385","author":"JY Viscondi","year":"2018","unstructured":"Viscondi JY, et al. Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening. Clinics. 2018. https:\/\/doi.org\/10.6061\/clinics\/2018\/e385.","journal-title":"Clinics"},{"issue":"4","key":"1713_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0272989X11408730","volume":"31","author":"KM Kuntz","year":"2011","unstructured":"Kuntz KM, et al. A systematic comparison of microsimulation models of colorectal cancer. Med Decis Mak. 2011;31(4):530\u20139.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1713_CR21","doi-asserted-by":"publisher","first-page":"e99978","DOI":"10.1371\/journal.pone.0099978","volume":"9","author":"PM McMahon","year":"2014","unstructured":"McMahon PM, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the national lung screening trial using comparative modeling. PLoS ONE. 2014;9(6):e99978.","journal-title":"PLoS ONE"},{"key":"1713_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch2","author":"J Thomas","year":"2019","unstructured":"Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S. Determining the scope of the review and the questions it will address. Cochrane Handb Syst Rev Interv. 2019. https:\/\/doi.org\/10.1002\/9781119536604.ch2.","journal-title":"Cochrane Handb Syst Rev Interv"},{"key":"1713_CR23","unstructured":"Bethesda (MD). Entrez programming utilities help. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK25501\/. Accessed 08 Feb 2020."},{"issue":"2","key":"1713_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0272989X16670638","volume":"37","author":"LA Campbell","year":"2016","unstructured":"Campbell LA, et al. Understanding the effects of competition for constrained colonoscopy services with the introduction of population-level colorectal cancer screening. Med Decis Mak. 2016;37(2):253\u201363.","journal-title":"Med Decis Mak"},{"issue":"2","key":"1713_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ijc.31314","volume":"143","author":"J-B Lew","year":"2018","unstructured":"Lew J-B, et al. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. Int J Cancer. 2018;143(2):269\u201382.","journal-title":"Int J Cancer"},{"issue":"7","key":"1713_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.11.010","volume":"21","author":"N Silva-Illanes","year":"2018","unstructured":"Silva-Illanes N, et al. Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review. Value Health. 2018;21(7):858\u201373.","journal-title":"Value Health"},{"issue":"12","key":"1713_CR27","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/cncr.29476","volume":"121","author":"C Printz","year":"2015","unstructured":"Printz C. Colorectal cancer incidence increasing in young adults. Cancer. 2015;121(12):1912\u20133.","journal-title":"Cancer"},{"issue":"15","key":"1713_CR28","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.2015.13183","volume":"314","author":"ER Myers","year":"2015","unstructured":"Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314(15):1615\u201334. https:\/\/doi.org\/10.1001\/jama.2015.13183.","journal-title":"JAMA"},{"issue":"4","key":"1713_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/GRF.0000000000000478","volume":"62","author":"A Bus-Kwofie","year":"2019","unstructured":"Bus-Kwofie A, et al. Clinical controversies in cervical cancer screening. Clin Obstet Gynecol. 2019;62(4):644\u201355.","journal-title":"Clin Obstet Gynecol"},{"issue":"6","key":"1713_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7326\/0003-4819-159-6-201309170-00690","volume":"159","author":"LL Humphrey","year":"2013","unstructured":"Humphrey LL, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Intern Med. 2013;159(6):411.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1713_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40985-018-0083-x","volume":"39","author":"K Selby","year":"2018","unstructured":"Selby K, et al. Personalized cancer screening: helping primary care rise to the challenge. Public Health Rev. 2018;39(1):1\u20138.","journal-title":"Public Health Rev"},{"key":"1713_CR32","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.jtho.2018.08.012","volume":"13","author":"H De Koning","year":"2018","unstructured":"De Koning H, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised controlled population based trial. J Thorac Oncol. 2018;13:S185.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1713_CR33","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382(10):917\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1910038.","journal-title":"N Engl J Med"},{"issue":"1","key":"1713_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0969141314559956","volume":"22","author":"SG Zelle","year":"2014","unstructured":"Zelle SG, et al. Predicting the stage shift as a result of breast cancer screening in low- and middle-income countries: a proof of concept. J Med Screen. 2014;22(1):8\u201319.","journal-title":"J Med Screen"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-021-01713-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-021-01713-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-021-01713-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T13:16:57Z","timestamp":1640006217000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-021-01713-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1186\/s12911-021-01713-5","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. We collect no primary data and hence there is no need for ethical review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}